Search
Leukemia Clinical Trials
A listing of 48 Leukemia clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 48
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Leukemia
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 48 active clinical trials seeking participants for Leukemia research studies. The states with the highest number of trials for Leukemia participants are California, New York, Illinois and Texas.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Transcranial Magnetic Stimulation (TMS) for Obsessive Compulsive Disorder (OCD)
Recruiting
Transcranial magnetic stimulation (TMS) is an FDA-approved, non-invasive form of brain stimulation for OCD. TMS has been shown to be an effective form of treatment in individuals with OCD. By using a form of TMS termed theta-burst stimulation (TBS), we hope that this will result in a more effective treatment by producing faster symptom reduction. We are trialing a novel form of accelerated TMS, where we will deliver ten 10-minute sessions per day, for 5 days. This study will compare the efficacy of TMS for OCD at two distinct brain regions. Participants will be randomized into one of two study groups, and receive stimulation at either the DMPFC or R-OFC. Both regions have been linked to OCD by research. Patients that don't respond to their study region will have the option to receive stimulation at the other region.
Conditions:
Obsessive-Compulsive Disorder
Obsessive Compulsive Disorder
Obsessive Compulsive Disorder (OCD)
Obsessive-Compulsive Disorder (OCD)
Obsessive-compulsive Disorders and Symptoms
Featured Trial
High Triglyceride Clinical Research Study
Recruiting
Living with high triglycerides? See if our clinical study is right for you.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Conditions:
High Triglycerides
High Triglyceride Level
Hypertriglyceridemia
Elevated Triglycerides
Triglycerides High
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Recruiting
This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or not responded to treatment.
Gender:
All
Ages:
Between 1 year and 39 years
Trial Updated:
01/24/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Leukemia
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Recruiting
The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and providers, improves patient-reported values-concordance of initial treatment decisions compared to usual care.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
01/23/2025
Locations: Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina
Conditions: Hematologic Malignancies, Lymphoma, Multiple Myeloma, Leukemia, Blood Cancers
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Recruiting
To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuzumab ozogamicin (called cRIB) can help to control the disease.
Gender:
ALL
Ages:
Between 1 year and 25 years
Trial Updated:
01/23/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Recruiting
The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. The doctors have identified the patient because 1) they have had a lymphoproliferative disorder such as lymphoma, leukemia, or multiple myeloma, and have a family member with one of these disorders or 2) they are a member of a family with a lymphoproliferative disorder, including Hodgkin's disease a... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/21/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +5 locations
Conditions: Lymphoma, Leukemia, Multiple Myeloma, Colon Cancer, Renal Cancer
Talazoparib for Cohesin-Mutated AML and MDS with Excess Blasts
Recruiting
This research study is testing if Talazoparib is an effective treatment for patients with AML and MDS that have a mutation in the cohesin complex.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +1 locations
Conditions: Leukemia
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Recruiting
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/15/2025
Locations: City of Hope Phoenix, Goodyear, Arizona +252 locations
Conditions: Leukemia
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Recruiting
The goal of this clinical research study is to learn if cladribine given in combination with low-dose cytarabine (LDAC) and decitabine can help control the disease in patients with AML or MDS. The safety of this drug combination will also be studied.
Cladribine is designed to interfere with the cell's ability to process DNA (the genetic material of cells). It can also insert itself into the DNA of cancer cells to stop them from growing and repairing themselves.
Cytarabine is designed to insert... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
01/09/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
Recruiting
To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
01/09/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, HOX Gene
Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families
Recruiting
This study will seek to improve communication with Spanish speaking families and patients with Cancer and Blood Disorders.
Gender:
ALL
Ages:
22 years and below
Trial Updated:
01/08/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Leukemia, Non Hodgkin Lymphoma
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
Recruiting
This is an open label, phase 1 study for AML subjects with relapsed or refractory disease or subjects in morphologic remission with MRD+ after first line therapy with venetoclax+HMA. A preliminary dose-finding cohort will be followed by 3 expansion cohorts.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/02/2025
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Leukemia, Myeloid Leukemia, Monocytic Leukemia
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Recruiting
This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy.
GEO-CM04S1 belongs to a category called modified vaccinia Ankara (MVA) vaccines, created from a new version of MVA, called synthetic MVA. GEO-CM04S1 works by inducing immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/31/2024
Locations: City of Hope Medical Center, Duarte, California +3 locations
Conditions: COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
Revumenib in Combination With 7+3 + Midostaurin in AML
Recruiting
This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostaurin) to participants with newly diagnosed Nucleophosmin (NPM1) and FMS-like tyrosine kinase 3 (FLT3) mutated Acute Myeloid Leukemia (AML).
The names of the study drugs involved in this study are:
* Re... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/30/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations, AML, Leukemia
1 - 12 of 48